chromatography using a Superdex-200 16/60 column (Pharmacia) and 50 mM Tris-HCl, 100 mM NaCl, pH 8.0 as running buffer. Protein eluting as a trimer was concentrated to 14 mg/ml. A typical yield of pure protein is approximately 8 mg per preparation as described above. Whereas the 1918 construct facilitated expression of unprocessed HA0 monomers (S3) , the Viet04 construct produced only cleaved (HA1/HA2) species (Fig. S2) . At this stage, Viet04 still contains the additional plasmid-encoded residues at both the N (ADPG) and C terminus (RSLVPR) Initial crystallization trials were set up using a Topaz™ Free Interface Diffusion (FID) Crystallizer system (Fluidigm Corporation, San Francisco, CA). Crystals were observed in approximately 34 of the 384 Optimix™ conditions tested (mostly in buffers containing PEG 3350 or PEG 4000). The most promising condition based on crystal quality (Opti4 #47; 18 % PEG 4000, 0.1 M Hepes, pH 7.5) was translated to sitting drop conditions. Subsequent optimization of these conditions yielded diffraction quality crystals.
Viet04 crystals were grown by the sitting drop vapor diffusion method with a reservoir solution (0.6 ml) of 22% PEG 2000, 0.1M Hepes, pH 6.55. Crystallization drops were set up at 17°C, with 0.6 l of protein mixed with an equal volume of reservoir solution. The resulting crystals were "flash-cooled" at a temperature of 100 K in a reservoir solution containing 20% glycerol. A dataset was collected to 2.95 Å resolution at the Advanced Light Source (ALS) beamline 8.2.2 at 100 K. The data were indexed in space group P3 with unit cell dimensions: a = b = 197.94 Å, c = 134.69 Å. Statistics for data collection are presented in Table S1 . Data were processed with the DENZO-SCALEPACK suite (S5) using all observations. The Viet04 structure was determined by molecular replacement with Phaser (S6). Initial searches using HA monomers as the search model failed and rotation solutions were only found when searches were initiated using a trimer. Two solutions were found using the trimeric crystal structure of the 1918 H1 human hemagglutinin [Protein Databank (PDB) ID: 1RD8] as the search model, truncated around the cleavage site (Z scores: 37.2 and log-likelihood gain: 3412) (S3) . From inspection of initial electron density maps, it became apparent that extra density was present and subsequent searches with HA monomer models found two more monomers. The best solution gave an R free = 45.4 and R cryst = 44.0 after initial rigid-body and restrained refinement with REFMAC (S7). The model was then "mutated" to the correct sequence, rebuilt using either O (S8) or Coot (S9) , and refined with REFMAC using TLS refinement (S7) . Electron density maps used during model building included 2F obs -F calc , F obs -F calc maps, solvent flattened average maps (generated using the density modification package within ccp4 (S7) and composite annealed omit 2F obs -F calc maps [the last-mentioned maps were generated using the program CNS (S10) ]. Subsequent refinement revealed obvious density for a final (9 th ) monomer in the asymmetric unit. However, because a solution for this third monomer of a crystallographic trimer could not be found using Phaser, the monomer was manually fitted into the density. Thus, six hemagglutinin monomers making two noncrystallographic trimers, related by a noncrystallographic 3-fold and three monomers that each form one-third of three crystallographic trimers occupy the asymmetric unit with an estimated solvent content of 57 % based on a Matthews' coefficient (V m ) of 2.9 Å 3 /Da (see Fig. S3 for illustration of crystal packing). Throughout model building/refinement, tight non-crystallographic symmetry restraints were applied to the six monomers in the non-crystallographic trimers. Progress during refinement was judged by monitoring the R free test set, for cross-validation (S11). The size of the test set (1233 reflections) was selected according to accepted guidelines (S12) where the number of reflections should be between 500 and 2000.
At later stages of refinement, N-linked carbohydrates were built at 16 of the 45 potential glycosylation sites in the asymmetric unit. The final Viet04 model has an R cryst of 26.9 % and R free of 31.9 % (see Table S1 ). The quality of the model was checked with the program PROCHECK (S13) and Molprobity (S14). For the Ramachandran plot, 98.4% of the residues were in the most favored (79.2%) and additionally allowed regions (19.2%). The final PDB is numbered according to H3 numbering, based on structural overlay with the H3 structure (PDB: 2hmg). Residues deemed to be insertions are numbered XA, where X is the preceding residue number in the chain (e.g., Asn
19A in HA1).
Glycan array fabrication and glycan array analyses
Microarray printing has been described previously (S15). HA-antibody precomplexes were prepared by mixing HA (1 mg/mL, 15 l), mouse anti-penta-His-Alexa Fluor488 (0.2 g/mL, 35 l, Qiagen, Valencia, CA) and anti-mouse-IgG-Alexa Fluor488 (2.3 L, 2 mg/ml) in a molar ratio of 4:2:1, respectively. Mixtures were incubated for 15 min on ice, diluted with PBS buffer containing 3% bovine serum albumin (50 l) and incubated on the microarray slide under a microscope cover glass in a humidified chamber for 30 min. Slides were subsequently washed by successive rinses in PBS with 0.05 % Tween-20, PBS, and deionized water, then immediately subjected to imaging as previously described (S15). Figure S1 . Gel filtration and SDS-PAGE analysis of Viet04 HA construct. The clone was engineered so that the resulting HA0 ectodomain was fused to a C-terminal linker containing a thrombin cleavage site, a foldon trimerizing sequence from T4 bacteriophage (S4) and a hexa His-tag to aid purification (18HA0zip). (A) This construct expressed trimeric material that eluted at >200 kD (blue trace) after gel filtration. After thrombin cleavage, protein eluted as stable trimers (red trace) and yielded diffractable crystals. The figure represents superimposed elution profiles of two separate experiments overlaid with calibration standards (black line). (B) Uncleaved HA protein ran as doublet bands of the HA1 and HA2 monomers (HA1; 40 kD and HA2; 20 kD) on an SDS-PAGE gel. After thrombin cleavage, as expected, only the HA2 band decreased in size due to the removal of the foldon trimerizing domain from its C terminus. Tables for Crystallography) . Crystallographic trimers are labeled with an orange triangle, whereas noncrystallographic trimers are unlabeled. Figure S3 . Analysis of Viet04 cleavage site. Cleavage of the polybasic site of Viet04 separates the HA1 C terminus (only up to Pro 324 is observed) from the fusion peptide at the N terminus of HA2, which is stabilized by hydrogen bonds (green dots) from Asp B112 , as well as Ser F113 in an adjacent monomer. Figure S5 . Sequence alignment of the amino acid sequences of the human H5 HAs (deposited in the sequence databases, as of October 2005). Only residues that differ from the top sequence (A/Hong Kong/156/1997) are shown. Sequences are separated into the years of the isolates. Red numbering corresponds to the H3 numbering used for structural analysis (S1). Residues marked < and > are the start/stop sites for the expressed Viet04 construct. Residues shaded green indicate potential glycosylation sites (N-X-S/T), grey indicates the transmembrane domain, boxed residues is the polybasic cleavage site for each gene product, and red are the antigenic sites identified previously in H5 HAs (S16, S17 Figure 3A) , whereas the Ser and H9 (PDB: 1jsd) were superimposed by sequence and structural alignment onto the equivalent domains of Viet04. The following residues were used for superimposition and calculation of the RMSD. values for the HA2 domain: Viet04: A13 to A51, A276 to A324, B21 to B160; 1918-hu-H1: A13 to A51, A276 to A324, B21 to B160; 1934-hu-H1: A7 to A45, A270 to A318, B521 to B660; 1930-sw-H1: A7 to A46, A270 to A318, B521 to B660; hu-H3: A13 to A51, A276 to A324, B21 to B160; av-H5: A3 to A41, A273 to A321, B21 to B160; av-H7: A13 to A51, A276 to A3245, B21 to B160, and sw-H9: A3 to A41, A267 to A315, B1 to B160. After superimposition, the following residues were used to compare the HA1 domains: Viet04: A52 to A275; 1918-hu-H1: A52 to A275; 1934-hu-H1: A46 to A269; 1930-sw-H1: A47 to A269; hu-H3: A52 to A275; av-H5: A42 to A272; av-H7: A52 to A275 and sw-H9: A42 to A266. The HA1 domain was further divided into the Receptor (R) and vestigial Esterase (E) regions. The following residues were used to compare to R regions: Viet04: A117 to A265; 1918-hu-H1: A117 to A265; 1934-hu-H1: A111 to A259; 1930-sw-H1: A111 to 259; hu-H3: A117 to A265; av-H5: A110 to A262; av-H7: A117 to A265 and sw-H9: A110 to A256. The following residues were compared for the E regions: Viet04:A52 to A116, A266 to A275; 1918-hu-H1: A52 to A116, A266 to A275; 1934-hu-H1: A46 to A110, A260 to A269; 1930-sw-H1: A47 to A110, A260 to A269; hu-H3: A52 to A116, A266 to A275; av-H5: A42 to A109, A263 to A272; av-H7: A52 to A116, A266 to A275 and sw-H9: A42 to A109, A257 to A266. For the column labeled monomer, both HA1 and HA2 were used in the calculations. 18 ** ** ** ** ** ** nb ** ** nb ** ** 19 nb ** nb nb ** nb nb nb nb nb nb nb 20 ** nb ** ** ** ** ** ** ** ** ** ** 21 * ** nb ** ** ** nb ** * nb ** ** 22 nb ** nb ** ** ** nb ** nb nb ** ** 23 * ** nb ** ** ** nb ** ** nb ** ** 24 * ** ** ** ** ** nb ** ** ** ** ** 25 * ** ** ** nb ** ** ** ** ** ** ** 26 nb ** nb ** ** ** nb ** ** nb ** nb 27 nb ** nb ** ** ** nb ** * 
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